We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Intelligent Ultrasound Group Plc | LSE:MED | London | Ordinary Share | GB00BN791Q39 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.50 | 14.00 | 15.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMED
RNS Number : 1769K
Medaphor Group PLC
12 December 2018
The information contained within this announcement (the "Announcement") is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this Announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.
MedaPhor Group plc
("MedaPhor" or the "Company")
Results of Open Offer
MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, is pleased to announce that further to the announcement of the Placing and Open Offer on 26 November 2018, it has conditionally raised total gross proceeds of GBP78,778 via the Open Offer.
The Open Offer closed for acceptances at 11.00 a.m. on 11 December 2018. The Company received valid acceptances from Qualifying Shareholders in respect of 926,801 Open Offer Shares, including applications for 63,354 Open Offer Shares under the Excess Application Facility. This represents 3.8 per cent. of the maximum Open Offer Shares available under the Open Offer. Admission of the Open Offer shares is subject to passing the relevant resolutions at the General Meeting.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 26 November 2018.
Enquiries:
Hot Features
Premium
MedaPhor Group plc www.medaphor.com
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Wilson Jennings, CFO
Cenkos Securities - Nominated Tel: +44 (0)20 7397 8900
Advisor and broker
Mark Connelly / Cameron MacRitchie
(Corporate Finance)
Michael Johnson / Julian Morse
(Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com
Anna Dunphy / Paul McManus Mob: +44 (0)7876 741 001 / Mob:
+44 (0)7980 541 893
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ROIEANAFFLDPFFF
(END) Dow Jones Newswires
December 12, 2018 02:00 ET (07:00 GMT)
1 Year Intelligent Ultrasound Chart |
1 Month Intelligent Ultrasound Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
